JUN 2 3 2004

PTO/SB/08a (08-03) Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Page work Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

5

ANEX Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

1

Complete if Known Application Number 10/724,266 Filing Date November 26, 2003 First Named Inventor Barbara Enenkel et al <del>1692</del> 1636 Art Unit **Examiner Name** To be assigned J. Ketter Attorney Docket Number | 1/1412

Sheet U. S. PATENT DOCUMENTS Name of Patentee or Applicant of Cited Document Pages, Columns, Lines, Where Publication Date **Document Number** Relevant Passages or Relevant Figures Appear Examine MM-DD-YYYY Initials\* Number-Kind Code<sup>2 (F known)</sup> Barbara Enenkel et al US-6,063,598 05/16/2000 JK Gordon M. Ringold US-4,656,134 04/07/1987 Richard Axel et al 01/12/1993 US- 5,179,017 Martin Chalfie et al US- 5,491,084 02/13/1996 Martin Chalfie et al <sup>US-</sup> 6,146,826 11/14/2000 US-US-US-US-US-US-US-US-US-บร USus-US

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> (Number <sup>4</sup> Yand Code <sup>5</sup> ( <i>If known</i> )	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	τ°		
JK		WO 97/15664	05/01/1997	Dr. Karl Thomae GmbH		<u> </u>		
<u> </u>		WO 98/32869	07/30/1998	Neurosearch		<u> </u>		
,,,,,,,,,,	<b>†</b>	WO 02/094325 A2	11/28/2002	Boehringer Ingelheim International		上		
	<b>†</b>	WO 01/04306 A1	01/18/2001	Genentech, Inc.		╄		
	<b></b>	WO 99/53046	10/21/1999	Chiron Corporation	<u> </u>	<u></u>		

Examiner Signature	/James Ketter/	Date Considered	09/19/2006
Signature	•		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English tanguage

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, useful of the USPTO. Time will vary depending upon the individual case. Any comments including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450.

ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

JUN 2/3 2004 THE PAREN

PTC/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

ter the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO **Application Number** 10/724,266 Filing Date Novemebr 26, 2003 INFORMATION DISCLOSURE First Named Inventor Barbara Enenkel et al STATEMENT BY APPLICANT Art Unit <del>1892</del> 1636 <del>To be assigned</del> J. Ketter Examiner Name (Use as many sheets as necessary) Attorney Docket Number 1/1412 5 Sheet

		<del></del>	U. S. PATENT C	Name of Patentee or	Pages Columns Lines Where
xaminer	Cite No.	Document Number	Publication Date MM-DD-YYYY	Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant
ritials*	No.	Number-Kind Code <sup>2 (8 known)</sup>	MM-UD-TTTT	Applicant of Gred Document	Figures Appear
		US-			
		US-			
		US-			
		ŪS-			
	1	US-			
	<b> </b>	US-			
	<b></b>	US-			
	<u> </u>	US-			
	<del> </del>	US-			
	1	US-			
	<del>                                     </del>	US-			
		US-			
	1	US-			
		US-			
	╁	US-			
	1	US-			
	1	US-			
	-	US-	-		

	FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> Number <sup>4</sup> 'Kind Code <sup>8</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>			
JK		DE 19539493 A1	04/30/1997	Dr. Karl Thomae GmbH					
					***************************************				
				<b>7</b> 14441646666666666666666666666666666666	***************************************				
				P 1000 1000 1000 40 40 40 40 100 100 100		<u> </u>			
	<u> </u>					<u> </u>			

		T-0-4-	00/10/2006
Examiner	/James Ketter/	Date	09/19/2006
Signature	/James Ketter/	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and no considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

•					
Cubatituda far	form 1449B/PTO				Complete if Known
Substitute to:	101111144557710			Application Number	10/724,266
INFOR	RMATION DI	SCLO	SURE	Filing Date	November 26, 2003
	EMENT BY			First Named Inventor	Barbara Enenkel et al
JIAI				Art Unit	<del>1002</del> 1636
	(Use as many sheets as	necessary)	)	Examiner Name	Tobe assigned J. Ketter
 Sheet	3	of	5	Attorney Docket Number	1/1412

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
JК		CHARLES G. BAILEY ET AL; High-Throughput Clonal Selection of Recombinant CHO Cells Using a Dominant Selectable and Amplifiable Metallothionein-GFP Fusion Protein; Biotechnology and Biomolecular 12/20/2002 Vol. 7 page 670-676; Wiley Periodicals, Inc.	ļ
JK		XUEDONG LIU ET AL; Generation of Mammalian Cells Stably Expressing Multiple Genes at Predetermined Levels; Analytical Biochemistry (2000) Vol. 9 pages 20-28; Academic Press	
JK		ROBERT P. BENNETT ET AL; Fusion of Green Fluorescent Protein with the Zeocin TM-Resistance Marker Allows Visual Screening and Drug Selection of Transfected Eukaryotic Cells; Biotecniques (March 1998) Vol. 24 No. 3 pages 478-482; Invitrogen Corporation, Carlsbad, CA, USA	
JK		Y. GLORIA MENG ET AL; Green fluorescent protein as a second selectable marker for selection of high producing clones from transfected CHO cells; Gene (2000) Vol. 242 pages 201-207; Elsevier Science B.V.	
JK		D.D. MOSSER ET AL; Use of a Dicistronic Expression Cassette Encoding the Green Fluorescent Protein for the Screening and Selection of Cells Expressing Inducible Gene Products; Biotechniques (January 1997) Vol. 22 No. 1 pages 150-161; National Research Council, Montreal Canada	
JK		NO SOO KIM ET AL; Key Determinants in the Occurance of Clonal Variation in Humanized Antibody Expression of CHO Cells during Dihydrofolate Reductase Mediated Gene Amplification;  Extractor Prog. (2001) Vol. 17 pages 69-75; American Chemical Society.	
JK		ROLF G. WERNER ET AL; Appropriate Mammalian Expression Systems for Biopharmaceuticals; Drug Research (1998) Vol. 8 pages 870-880; Boehringer Ingelheim Pharma KG, Biberach Germany	
JK		GAIL URLAUB ET AL; Delection of the Diploid Dihydrofolate Reductase Locus from Cultured Mammalian Cells; Cell (June 1983) Vol. 33 pages 405-412; Department of Biological Sciences Co: mb'a Un'versity. New York. NY.	
JK		YOSHIKAZU SUGIMOTO ET AL; Efficient Expression of Drug-selectable Genes in Retroviral Vectors Under Control of an Internal Ribosome Entry Site; Biotechnology (July 1994) Vol. 12 pages 504, 508; Netional Capper Institute	_
JK		N. RAMESH ET AL; High-titer biclstronic retroviral vectors employing foot-and-mouth disease virus internal ribosome entry site; Nucleic Acids Research (1996) Vol. 24 No. 14 pages 2697-2700; Oxford University Press	<u>.</u>

	(Offiversity 1 rese		
Examiner	/James Ketter/	Date Considered	09/19/2006
Signature			

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation is attached.

2 Applicant is to place a check mark here if English language Translation is attached.

3 Applicant's unique citation designation is attached.

4 Applicant's unique citation designation is attached.

5 Applicant's unique citation designation is attached.

6 Applica

Approved for use through 06/30/2006. OMB 6651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Substitute for	form 1449B/PTO			Complete If Known			
					Application Number	10/724,266		
	INFOR	RMATION DI	SCLO	SURE	Filing Date	Novemebr 26, 2003		
	STAT	EMENT BY	APPLI	CANT	First Named Inventor	Barbara Enenkel et al		
	• • • • • • • • • • • • • • • • • • • •				Art Unit	<del>1632</del> 1636		
		(Use as many sheets a:	necessary	)	Examiner Name	To be assigned J. Ketter		
_	Sheet	4	of	5		1/1412		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	τ²
JK		MICHAEL PRIMIG 1 ET AL; A novel GFPneo vector designed for the isolation and analysis of enhancer elements in transfected mammalian cells; International Journal of Genes and Genomes (1998) Vol 215 pages 181-189; Elsevier Science B.V.	
JK		JERRY PELLETIER ET AL; Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from pollovirus RNA; Nature (July 1988) Vol. 334 pages 320-325; Department of Biochemistry McGill Cancer Center, McGill University Montreal Canada	ļ
JK		RICHARD A. MORGAN ET AL; Retroviral vectors containing putative internal ribosome entry sites: development of a polycistronic gene transfer system and applications to human gene therapy; Nucleic Acids Research (February 10, 1992) Vol. 20 No. 6 pages 1293-1299; Molecular Hernatology Branch, Bethesda MD.	
JK		LUCIA MONACO ET AL; Expression of recombinant human granulocyte colony-stimulating factor in CHO dhfr -cells: new insights into the in vitro amplification expression system; Gene (1996) Vol. 180 pages 145-150; Elsevier Science B.V.	
JK		VICTOR V. LEVENSON ET AL; Internal Ribosomal Entry Site-Containing Retroviral Vectors with Green Fluorescent Protein and Drug Resistance Markers; Human Gene Therapy (May 20, 1998) Vol. 9 pages 1233-1236; Department of Molecular Genetics, University of IL. Chicago, IL.	
JK		RANDAL J. KAUFMAN; Selection and Coamplification of Heterologous Genes in Mammalian Cells; Methods in Enzymology Vol. 185 No. 42 pages 537-566; Academic Press, Inc.	
JK		SUNG K. JANG ET AL; Initiation of Protein Synthesis by Internal Entry of Ribosomes into the 5' Nontranslated Region of Encephalomyocarditis Virus RNA In Vitro; Journal of Virology (April 1989) Vol. 63 No. 4 Pages 1651-1660; American Society for Microbiology	
JK		CORD HEMANN ET AL; High-Copy Expression Vector Based on Amplification-Promoting Sequences; DNA and Cell Biology (1994) Vol. 13 No. 4 Pages 437-445; Mary Ann Liebert, Inc Publishers	
JK		ALEXANDER N. GUBIN ET AL; Long-Term, Stable Expression of Green Fluorescent Protein in Mammalian Cells; Biochemical and Biophysical Research Communications (1997) Vol. 236 pages 347-350: Academic Press	
JK		MARTIN CHALFIE ET AL; Green Fluorescent Protein as a Marker for Gene Expression; Science (February 11, 1994) Vol. 263 pages 802-805; Department of Biological Sciences, Columbia University New York, NY	

4				09/19/2006
	Examiner	/James Ketter/	Date	03/13/2000
ı	Signature	/ Cumes Receel/	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not cliation is in conformance with MPEP out. Draw line unough cleated in the incomplete considered. Include copy of this form with next communication to applicant.

Applicant's unique cliation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of Information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTC/SB/08b (08-03)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

		_			
Substitute for fo	ım 1449B/PTO				Complete if Known
				Application Number	10/724,266
INFOR	MATION [	DISCLOS	SURE	Filing Date	November 26, 2003
STATE	MENT BY	'APPLIC	CANT	First Named Inventor	Barbara Enenkel
				Art Unit	<del>1032</del> 1636
(L	lse as many sheets	as necessary)		Examiner Name	Tobe assigned J. Ketter
Sheet	5	of	5		1/1412

NON PATENT LITERATURE DOCUMENTS							
Examiner Cite No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
JK		MONIQUE V. DAVIES ET AL; The Sequence Context of the Initiation Codon in the Encephalomyocarditis Virus Leader Modulates Efficiency of Internal Translation Initiation; Journal of Virology (April 1992) Vol. 66 No. 4 pages 1924-1932; American Society for Microbiology					
JK		MOHAMMED A. ADAM ET AL; Internal Initiation of Translation in Retroviral Vectors Carrying Picornavirus 5' Nontranslated Regions; Journal of Virology (September 1991) Vol. 65 No. 9 pages 4985-4990; American Society for Microbiology					
JK	ĺ	RANDAL J. KAUFMAN ET AL; Amplification and Expression of Sequences Cotransfected with a Modular Dihydrofolate Reductase Complementary DNA Gene; J. Mol. Biol. (1982) Vol. 159 pages 601-621; Center for Cancer Research and Department of Biology. Cambridge Mass.					
JK		International Search Report Refemce No. PCT/EP 03/13225					
	••••••						
•••••••••••••••							
	ļ	·	-				

	/James Ketter/		1 1	09/19/2006
Examiner	\names verrei\		Date	03/13/2000
Examiner				
Signature		•	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here flenglish language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.